Verona Pharma plc diskutieren
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target lowered by analysts at HC Wainwright from $33.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at HC Wainwright from $32.00 to $36.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Truist Financial Co. from $32.00 to $38.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $50.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Truist Financial Co. from $38.00 to $44.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at HC Wainwright from $36.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Wells Fargo & Company from $50.00 to $64.00. They now have an "overweight" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $57.00 price target on the stock, up previously from $44.00.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Wells Fargo & Company from $64.00 to $74.00. They now have an "overweight" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Neueste Beiträge
B__Riley in WAVE Life Sciences Ltd diskutieren